Akebia Therapeutics Inc. Stock
Price
Target price
€1.15
€1.15
0.000%
-
0.000%
€5.54
06.02.26 / Stuttgart Stock Exchange
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akebia Therapeutics Inc. Stock
There is no change in the price for Akebia Therapeutics Inc. today.
Akebia Therapeutics Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
Based on the current price of 1.15 € the target price of 5 € shows a potential of 335.16% for Akebia Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Akebia Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | 0.000% | -1.373% | -11.683% | -44.169% | -13.868% | 11.770% | -71.559% |
| Evolus Inc | -2.140% | -11.165% | -24.066% | -70.720% | -32.844% | -55.366% | -42.633% |
| Madrigal Pharmaceuticals inc. | -1.540% | -1.444% | -7.372% | 27.087% | -17.834% | 69.256% | 296.515% |
| Heron Therapeutics Inc. | -2.070% | -8.936% | -10.759% | -36.310% | -3.950% | -56.907% | -93.419% |
Comments
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
